Hybrigenics achieves first research milestone for Servier

20/01/2014

Paris, 20 January 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments for proliferative diseases, today announces the achievement of a first drug discovery milestone in connection with the ongoing research collaboration with Servier on ubiquitin-specific proteases (USPs) and their inhibitors. Hybrigenics has received EUR 0.33 million in recognition of this achievement.

The research collaboration with Servier was initiated in October 2011 (see Hybrigenics’ press release of October 10, 2011). Hybrigenics provides its expertise in target identification and validation among the numerous USPs for various therapeutic indications. Hybrigenics also ascertains the in vitro potency and selectivity of USP inhibitors of pharmacological interest.

“The successful achievement of this first milestone validates Hybrigenics’ cutting edge know-how in the field of USPs and its relevance to drug discovery. We look forward to the next steps towards a potential new drug, hand in hand with Servier’s R&D organization,” said Remi Delansorne, Hybrigenics’ CEO.

“We are very pleased to have achieved this first milestone of collaboration demonstrating how Hybrigenics’ technology and scientists can be a valuable complement to our internal activities in the field of oncology,” said Dr Emmanuel Canet, Head of Servier R&D.

About Hybrigenics
Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases. Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy in the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol is currently being tested in chronic lymphocytic leukemia patients.
Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes, and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.
Hybrigenics Services (www.hybrigenics-services.com), a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified highthroughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform. Hybrigenics also provides state-of-the-art genomic services specialized in DNA chips, DNA or RNA target enrichment, and next generation sequencing.
Hybrigenics Corp., based in Cambridge, Mass., USA, is a fully-owned American subsidiary of Hybrigenics.

About Servier Group
“Since the company’s creation, all of our profits are ploughed back into research” - Jacques Servier, Founding President of the Group.
Founded in 1954, Servier is the first independent French pharmaceutical research company. Its development is based on the continuous pursuit of innovation in the therapeutic areas of cardiovascular, metabolic, neurologic, psychiatric, bone and joint diseases as well as cancer. In 2012, the company recorded a turnover of 3.9 billion euros.
92% of Servier drugs are consumed internationally.
25% of turnover from Servier drugs is reinvested in Research and Development every year.
With a strong international presence in 140 countries, Servier employs more than 22 000 people worldwide.
The Servier Group contributed 57% to the 2012 French trade surplus in the pharmaceuticals sector.

***

HYBRIGENICS is listed on the Alternext market of Euronext Paris
ISIN: FR0004153930
Ticker: ALHYG

***

CONTACT
Servier
Communication Department
Tel. : +33 (0)1 55 72 60 37
presse@servier.fr

Hybrigenics
Rémi Delansorne
CEO
Tel. : +33 (0)1 58 10 38 00
investors@hybrigenics.com
NewCap.
Financial communication
Julien Perez / Pierre Laurent
Tel. : +33 (0)1 44 71 94 94
hybrigenics@newcap.fr